Last reviewed · How we verify
Staphylococcus Chronic Bronchitis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zymar | GATIFLOXACIN | Allergan | DNA gyrase, DNA gyrase, DNA gyrase subunit A | 2003-01-01 | ||
| Avelox | moxifloxacin | Bayer AG | Fluoroquinolone antibiotic (fourth-generation) | DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A | 1999-12-10 | |
| Avelox | Avelox | Novartis Pharmaceuticals | DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Staphylococcus Chronic Bronchitis
- Allergan · 1 drug in Staphylococcus Chronic Bronchitis
- Bayer AG · 1 drug in Staphylococcus Chronic Bronchitis
- Novartis Pharmaceuticals · 1 drug in Staphylococcus Chronic Bronchitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Staphylococcus Chronic Bronchitis:
- Staphylococcus Chronic Bronchitis treatment updates — RSS
- Staphylococcus Chronic Bronchitis treatment updates — Atom
- Staphylococcus Chronic Bronchitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Staphylococcus Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcus-chronic-bronchitis. Accessed 2026-06-10.
Related
- Staphylococcus Chronic Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing